Rapimelt tablets of nimodipine can be successfully prepared by direct compression method using selected superdisintegrants with Crosspovidone 1.5%, 3%, 6%, Crosscarmellose 1.5%, 3%, 6% and Sodium starch glycolate 1.5%, 3%, 6%, for the better patient compliance and effective therapy the relative efficiency of these superdisintegrants to improve the disintegration and dissolution rate of tablets were found in order. The disintegration of NF1, NF2, NF3 with 1.5%, 3%, 6% Crosspovidone formulations to be as 8, 6, 5secs respectively and is almost better than NF4, NF5, F6, NF7, NF8, N F9 formulations, formulation NF3 In-vitro Dissolution studies 10 minutes almost total amount of the drug is released 6% crosspovidone (i.e. 96.96%). Crosspovidone shows good result as compare to other superdisintegrants. Crosspovidone > crosscarmellose sodium > sodium starch glycollate. The drug release profiles of Nimodipine rapimelt tablets were fitted to various kinetic models such as Zero order, First order, Higuchi, Peppas and Hixson-Crowell. The dissolution parameters such as dissolution efficiency (DE) at 10 and 30 minutes were increased proportionately. Half-life of drug i.e., T50 was found to be 1.81, 1.70, 1.53, 2.42,1.94,1.59, 2.81, 1.98 and 1.73min for NF1, NF2, NF3, NF4, NF5, NF6, NF7, NF8 and NF9 formulations respectively. Shelf-life of the drug i.e.,T90 was found to be 9.75, 8.75, 8.24, 9.28 and 8.92 minutes for NF1, NF2, NF3, NF5 and NF6 formulations respectively. The drug release patterns of nimodipine fast dissolving tablets had followed the first order kinetic model. This release patterns are evident with the correlation coefficient ‘r’ values which are nearer to 1. The optimized formulation NF3 is kept for stability studies. Accelerated stability studies were carried out at 400C/75% RH for 3 months. The tablets were then evaluated for hardness, friability, disintegration and drug content at 1st month, 2nd month and 3rd month. The results indicated that there was no significant change in evaluation of the tablets. In-vivo Studies the limit had been sufficient for PK studies of Nimodipine. From the pharmacokinetic analysis, it can be concluded that the in vivo studies mimic the in vitro results. In vitro results demonstrated considerable difference in the percentage drug release between pure drug and Optimized formulation, similarly differences were observed in Cmax, Tmax and AUC0-t between pure drug and optimized formulations. The average peak plasma concentration obtained for the drug and fast-dissolving tablet, indicated an increase in the extent of absorption (AUC0-t). The decrease in the Tmax values indicated faster absorption from the optimized formulation and increase in the Cmax values indicated higher attainable plasma drug concentrations with the same dose of the drug. The higher values of PK parameters (AUC0-t, Cmax, Tmax and t½) showed enhancement in bioavailability of Nimodipine by formulating fast-dissolving tablet. The in vivo studies clearly indicated that Standard Drug approach can be adopted for formulation of Nimodipine tablets in order to achieve a faster onset of action.